{"id":"tocilizumab-400mg","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Infection (including serious infections)"},{"rate":"10-20","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"10-15","effect":"Hyperlipidemia"},{"rate":"5-10","effect":"Neutropenia"},{"rate":"0.1-1","effect":"Gastrointestinal perforation"},{"rate":"5-10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1237022","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tocilizumab binds to both soluble and membrane-bound IL-6 receptors, preventing IL-6 from activating immune cells and triggering the inflammatory cascade. This mechanism suppresses systemic inflammation and is particularly effective in conditions driven by IL-6-mediated pathology, such as rheumatoid arthritis and cytokine release syndrome.","oneSentence":"Tocilizumab is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, inhibiting IL-6 signaling and reducing inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:57.933Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Giant cell arteritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Systemic sclerosis-associated interstitial lung disease"},{"name":"Cytokine release syndrome (including CAR-T cell-induced)"}]},"trialDetails":[{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT07334379","phase":"PHASE2","title":"Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study","status":"RECRUITING","sponsor":"Lorenzo delSorbo","startDate":"2025-10-20","conditions":"Acute Hypoxemic Respiratory Failure","enrollment":60},{"nctId":"NCT04479358","phase":"PHASE2","title":"Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2020-09-10","conditions":"COVID-19","enrollment":85},{"nctId":"NCT06927375","phase":"PHASE4","title":"A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy","status":"RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2024-12-12","conditions":"Thyroid-Associated Ophthalmopathy","enrollment":60},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04476979","phase":"PHASE2","title":"Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-07-16","conditions":"Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome), Virus Diseases","enrollment":453},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT04893031","phase":"","title":"Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study","status":"COMPLETED","sponsor":"Karadeniz Technical University","startDate":"2020-03-01","conditions":"Tocilizumab, COVID-19, Critical Care","enrollment":213},{"nctId":"NCT04412291","phase":"PHASE2","title":"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2020-06-11","conditions":"Covid-19","enrollment":120},{"nctId":"NCT04560205","phase":"PHASE1","title":"Tocilizumab in COVID-19 Lahore General Hospital","status":"UNKNOWN","sponsor":"Lahore General Hospital","startDate":"2020-05-01","conditions":"SARS-CoV Infection","enrollment":50},{"nctId":"NCT04310228","phase":"NA","title":"Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2020-03-08","conditions":"COVID-19","enrollment":150}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":2,"reaction":"OXYGEN SATURATION DECREASED"},{"count":2,"reaction":"SARS-COV-2 TEST POSITIVE"},{"count":2,"reaction":"TRANSAMINASES INCREASED"},{"count":1,"reaction":"ACUTE RESPIRATORY FAILURE"},{"count":1,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"BLOOD BILIRUBIN INCREASED"},{"count":1,"reaction":"BLOOD CREATININE INCREASED"},{"count":1,"reaction":"CITROBACTER INFECTION"},{"count":1,"reaction":"CRYSTAL NEPHROPATHY"}],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["control group"],"phase":"marketed","status":"active","brandName":"Tocilizumab(400mg)","genericName":"Tocilizumab(400mg)","companyName":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","companyId":"shanghai-ninth-people-s-hospital-affiliated-to-shanghai-jiao-tong-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tocilizumab is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, inhibiting IL-6 signaling and reducing inflammatory cytokine production. Used for Rheumatoid arthritis, Giant cell arteritis, Polyarticular juvenile idiopathic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}